Mochida Pharmaceutical Co., Ltd.

Osaka Bioscience Institute

Lsi Medience Corporation

Kamon Shirakawa

Shoji Furusako

Tomokazu Matsusue

Yoshitaka Hosaka

Tetsushi Kawahara

Motoyasu Honda

Katsuki Naitoh

Yumi Hotta

Hiroshi Takayama

Maximiliano Vasquez

Naoki Ogawa

Shigekazu Nagata

Man Sung Co

Chitose Orii

Naofumi Sato

Jiro Hirose

Atsuko Fujisawa

Toru Yamakawa

Norio Nakamura

Toshinori Kanamori

Eberhard Spanuth

Yoshikazu Okamura

Takeshi Matsuya

Shuzo Akiyama

Kenichiro Nakashima

Boris Ivandic

Shigeatsu Endo

Sadao Mori

Shouji Furusako

Ralf Thomae

Naotaka Kuroda

The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.

Anti-presepsin antibody

The present invention provides anti-presepsin polyclonal antibodies specifically binding to a peptide comprising an amino acid sequence of SEQ ID NO: 1. As a result, anti-presepsin polyclonal antibodies which have less variation in measured values between lot-to-lot differences of antibodies compared to S68 antibodies and thus suitable anti-presepsin polyclonal antibodies for presepsin measurement are provided.

Specifically purified anti-presepsin antibody

Disclosed is a prediction method for the prognosis of sepsis comprising measuring an sCD14-ST level in a sample. sCD14-ST, to be measured in the present invention, is a marker superior to procalcitonin, known as a marker to predict the prognosis in sepsis patients.

Method for prediction of prognosis of sepsis

Methods for detecting respiratory infection associated with bacterial infection are described, in which the values of soluble CD14 antigen subtype ('sCD14-ST') in the urine sample can be used to select a patient with a respiratory infection to whom antibiotic can be beneficially administered. The methods of this disclosure can also be used to determine the timing for ending administration of the antibiotic to the patient with respiratory infection associated with bacterial infection.

Diagnosis of respiratory tract infectious disease using urine specimens

According to the methods for detecting respiratory infection associated with bacterial infection of the present invention, the values of soluble CD14 antigen subtype ('sCD14-ST') in the blood sample can be used to select a patient with a respiratory infection to whom the antibiotic can be administered. The methods of this disclosure can also be used to determine the timing for ending administration of the antibiotic to the patient with respiratory infection.

Diagnosis of respiratory tract infectious disease using blood specimens

According to the method for detecting respiratory infection associated with bacterial infection of the present invention, the measured value of soluble CD14 antigen subtype ('sCD14-ST) in the urine sample can be used to select a patient with a respiratory infection to whom the antibiotic can be administered.

Diagnosis of respiratory tract infectious diseases using urine specimens

According to the method for detecting respiratory infection associated with bacterial infection of the present invention, the measured value of soluble CD14 antigen subtype ('sCD14-ST) in the blood sample can be used to select a patient with a respiratory infection to whom the antibiotic can be administered.

The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.

Anti-platelet membrane glycoprotein VI monoclonal antibody

The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof:

There are provided a soluble CD14 antigen which is a novel in vivo protein useful as a marker for diagnosing sepsis and has the following characteristic features 1) to 3):

Soluble CD14 antigen

The present invention provides an antibody prepared using a peptide as an antigen, the peptide having 8 to 30 amino acid residues selected from an amino acid sequence at positions 1 to 68 of human high-molecular-weight CD14, or an antibody that binds to a peptide having a specific amino acid sequence at a position among the positions 1 to 68. An assay kit for human low-molecular-weight CD14 using the antibody and an assay method of the present invention, preferably a sandwich method, are able to quantitatively or qualitatively determine human low-molecular-weight CD14 with high sensitivity and specificity in a simple manner, so that they are useful for the diagnosis of a patient suffering from sepsis.

Growing community of inventors

Tokyo, Japan

Kamon Shirakawa